Myths in pet joint health: 4 ‘beliefs’ debunked

Good mobility is central to every pet’s quality of life and freedom of movement. Behind every leap, stretch and stride are healthy, resilient joints. However, it’s not always clear which ingredients work best, when to start supplementation and how to ensure consistent results over time.

This article separates fact from fiction, tackling four of the most common myths surrounding pet mobility and collagen ingredients for joint health. It also explores age-related joint changes and smarter mobility solutions, such as low-dose native (undenatured) type II collagen that helps pets stay active for longer.

Myth 1: Mobility solutions are limited to senior pets

Mobility issues are more visible in older animals, but structural changes in cartilage can begin much earlier. Mature articular cartilage has limited regenerative capacity, while turnover of key components such as type II collagen can be very slow.¹

Over time, mechanical stress and natural ageing can contribute to cartilage degradation and joint conditions, including osteoarthritis,² often before obvious signs appear. 

This is where proactive nutrition comes in. As consumers take a more preventive approach to their own well-being, pet parents are increasingly applying the same mindset to their companions and seeking nutritional strategies that preserve vitality for longer.³

For pet nutrition brands, this creates an opportunity to move beyond senior-only positioning and develop life-stage inclusive mobility solutions.

Key takeaway: Joint health is lifelong, not age-locked. Proactive support can begin before mobility issues become visible.

Myth 2: Joint issues can only be managed medically

Medical interventions play an essential role in the management of diagnosed joint disorders, particularly where pain relief or clinical treatment is required. However, nutrition can also be an important complementary strategy that is often overlooked until significant problems arise.

Mobility support is still sometimes perceived as reactive rather than preventive, but brands have an opportunity to help pet owners better understand the value of early, consistent support at different life stages. Clear education can also lead to making more informed decisions before mobility issues become visible.

Key takeaway: Medicine manages diagnosed disease, while nutrition can support long-term mobility strategies. Both matter, but early nutritional support has the potential to change how joint issues evolve.

Myth 3: All collagen ingredients work the same way

Collagen is fast becoming a popular pet food ingredient, with applications in joints and mobility, skin and coat health and other areas. But collagen type and structure matter.

Type I collagen is predominantly found in skin, tendons and bone, while type II collagen is the primary form present in cartilage.⁴ Collagen accounts for around 60% of the dry weight of cartilage, and type II collagen represents 90–95% of this.⁵

Structure is also important. Native, or undenatured, collagens remain in their natural 3D triple-helix form. Native type II collagen maintains this structure, allowing it to trigger an immune-mediated mechanism known as oral tolerance.⁶ Through this specific mode of action, it targets joints and at low doses (0.4 mg/kg body weight or 25 ppm in feed). 

In contrast, hydrolysed collagens are broken down into a mixture of amino acids and peptides. These components are absorbed in the digestive tract and can contribute to collagen synthesis in the body.⁷ While they can still support joint health, they are not specific to joint tissues and typically require much higher doses, around 1–8 g/day depending on the weight of the dog, to deliver benefits.⁸

Key takeaway: Collagen is not one-size-fits-all. For targeted joint-health applications, the type, structure, mode of action and effective dose all matter.

Myth 4: Quality is not a priority in pet nutrition

The pet humanisation trend has fundamentally shifted expectations of what ‘good’ pet nutrition looks like. Today’s pet parents are seeking more than basic functionality – they expect formulations that reflect the quality standards they apply to their own health choices, including clinically validated ingredients, safety standards, traceability and responsible sourcing.

However, not all collagen ingredients are supported by the same level of evidence. Some products use ingredients with limited clinical backing or inclusion levels that may be too low to deliver meaningful results.

For manufacturers, supplier selection is therefore becoming more important. Several indicators signal a trusted ingredient partner: well-designed, clinically substantiated studies demonstrating efficacy, a clear mechanism of action and evidence showing benefits at defined, effective doses. In addition to these scientific markers, brands can look for third-party certifications, such as ISO (International Organisation for Standardisation) standards, GMP (Good Manufacturing Practice) compliance or traceability verifications.

Bioiberica’s Collavant® n2 native type II collagen meets the criteria for scientific credibility and quality assurance. With demonstrated efficacy at 40 mg/day, the ingredient enables pet food and supplement manufacturers to develop differentiated mobility products across formats, including tablets, chews, powders and liquids.

The ingredient has also received NutraStrong™ Collagen Verification, the first independent certification system dedicated to evaluating and verifying the identity, source, safety and quality of collagen ingredients and products. The certification provides additional substantiation around purity, source integrity, manufacturing standards and claim support.

Key takeaway: Ingredient quality is becoming central to pet mobility positioning. Evidence, dose, traceability and verification can help strengthen consumer trust and product differentiation.

A new breed of pet mobility support with Collavant® n2

Mobility is not a seasonal concern or a senior-only issue. It is a lifelong pillar of pet wellbeing and a growing area of functional pet nutrition.

For brands, this means moving beyond reactive positioning and considering how joint-health support can be addressed more proactively across different life stages. By investing in targeted, clinically validated ingredients and prioritising education, manufacturers can help reshape how mobility is understood and supported.

Ingredients such as Bioiberica’s Collavant® n2 native type II collagen reflect this shift, offering a science-backed solution for pet mobility formulations. Aside from its efficacy at a low dose, it is naturally derived, preservative-free and produced through Bioiberica’s circular economy model. It is also recognised by independent bodies, supporting its credibility, quality and market differentiation.

This combination of performance, quality and sustainability enables brands to create premium mobility products that earn the trust of today’s pet parents.

Discover how Collavant® n2 is helping to unlock smarter joint health and mobility solutions.

---

¹ Karpinski R, Prus A, Baj J, et al. (2025). Articular cartilage: structure, biomechanics, and the potential of conventional and advanced diagnostics. Applied Science, 15(12): 6896.
² Szponder T, Latalski M, Danielewicz A, et al. (2022). Osteoarthritis: pathogenesis, animal models, and new regenerative therapies. J Clin Med. 12(1): 5.
³ New Food. Examining the pet food market: approaches and alternatives. Accessed 9 March 2026.
⁴ Campos LD, de Almeida Santos V, Demuner Pimentel J, et al. (2023). Collagen supplementation in skin and orthopedic diseases: A review of the literature. Heliyon, 9(4): e14961.
⁵ Fox AJS, Bedi A, Rodeo SA. (2009). The basic science of articular cartilage. Sports Health, 1(6): 461–468.
⁶ Martinez-Puig D, Costa-Larrión E, Rubio-Rodríguez N, Gálvez-Martín P. (2023). Collagen supplementation for joint health: The link between composition and scientific knowledge. Nutrients.
⁷ Leon-Lopez A, Morales-Penaloza A, Martinez-Juarez VM, et al. (2019). Hydrolyzed collagen—sources and applications. Molecules, 24(22): 4031.
⁸ Frost & Sullivan. Growth opportunities in global pet food ingredients 2024–2030.